

Genetic literacy series: genetic epilepsy with febrile seizures plus

Kenneth A. Myers¹, Ingrid E. Scheffer^{1,2,3},
Samuel F. Berkovic¹, on behalf of the ILAE Genetics
Commission*

¹ Epilepsy Research Centre, Department of Medicine, The University of Melbourne,
Austin Health, Heidelberg, Victoria

² Department of Paediatrics, Royal Children's Hospital, The University of Melbourne,
Flemington, Victoria

³ The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia

Received March 24, 2018; Accepted May 27, 2018

Genetic Literacy Series:

Genetic Epilepsy with Febrile Seizures Plus (GEFS+)

- Genetic epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome in which affected individuals within a family typically have a variety of epilepsy phenotypes.
- The most common GEFS+ phenotype is febrile seizures (FS) followed by febrile seizures plus (FS+).
- FS+ is defined as either or both of the following:
 - A. Febrile tonic-clonic seizures that begin before 3 months and/or continue after 6 years
 - B. Occurrence of both febrile and afebrile generalized tonic-clonic seizures.
- The GEFS+ spectrum comprises a heterogeneous group of generalized and focal epilepsy phenotypes including the developmental and epileptic encephalopathies of epilepsy with myoclonic-atonic seizures and Dravet syndrome.

Genetic Literacy Series:

Genetic Epilepsy with Febrile Seizures Plus (GEFS+)

- Mutations in *SCN1A* are the most common identified genetic cause of GEFS+, accounting for approximately 19% of families.
- Whether clinical molecular genetic testing in patients with FS+ or other GEFS+ phenotypes is indicated is currently under debate.
 - If genetic testing is offered, *SCN1A* sequencing should be included, and this may be most efficiently performed as part of a panel or whole-exome sequencing.